ClinicalTrials.gg
CompletedNCT02163499Updated Jun 27, 2018Results posted

Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months

A Phase 3 interventional study of Sodium Zirconium Cyclosilicate in Hyperkalemia, sponsored by ZS Pharma, Inc.. Completed at 51 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-27.

Sponsored by ZS Pharma, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
751
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia — 3 open to participants now, 4 under way, none of them phase 3. sodium zirconium cyclosilicate · Hyperkalemia.

Enrollment
3rd of 27
751 · median 120
Started
2014
with 2 others
Phase 3
12 of 27
none open now
Registered
3rd of 27
by date
Lead sponsor
3 of 27
ZS Pharma, Inc.

Among the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, this one is the 3rd largest by enrollment, is one of 3 that started in 2014, is one of 12 in phase 3, and was the 3rd registered.

Hyperkalemia

134 studies on the registry are indexed under Hyperkalemia; 26 are open to participants now.

Browse Hyperkalemia studies →

Open to participants now

3 of the 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sodium zirconium cyclosilicate

sodium zirconium cyclosilicate: first FDA approval 2018 (LOKELMA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Hyperkalemia studies recruiting now, 11 (69%) set no upper age limit and 2 (13%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing sodium zirconium cyclosilicate in Hyperkalemia, or all of them as a file.
02

Study summary

The Open-Label Maintenance Study contains an Acute Phase, in which subjects will be dosed with ZS 10 g three times daily (tid) for 24 to 72 hours, followed by a long-term Maintenance Phase.

Read the detailed description

Subjects with 2 consecutive i STAT potassium values 5.1 mmol/L will enter the Acute Phase and receive ZS 10 g tid for 24 to 72 hours, depending on potassium values. Once normokalemia (i STAT potassium between 3.5 and 5.0 mmol/L, inclusive) is restored (whether after 24, 48 or 72 hours), subjects will be enrolled in the Maintenance Phase to be dosed with ZS at a starting dose of 5 g qd. Potassium (i STAT and central laboratory) will be measured weekly throughout the first month of study and every 4 weeks thereafter through Month 12. During the Maintenance Phase, the ZS dose may be increased or decreased in increments/decrements of 5 g qd up to a maximum of 15 g qd or a minimum of 5 g every other day based on i STAT potassium measurements as outlined below:

  • > 5.0 mmol/L while receiving 5 g qd or 5 g every other day or > 5.5 mmol/L while receiving 10 g qd: increase ZS dose in 5 g qd increments to a maximum dose of 15 g qd

.• Between 3.0 and 3.4 mmol/L, inclusive: decrease ZS dose in 5 g qd decrements to a minimum dose of 5 g every other day; if a subject's i STAT potassium value remains between 3.0 and 3.4 mmol/L, inclusive, on the ZS 5 g every other day dose, the subject will be withdrawn from the study and receive standard of care treatment.

There is no limit to the number of dose titrations allowed. Subjects will receive up to 12 months of treatment with open-label ZS.

03

Conditions studied

  • Hyperkalemia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of written .
  • Over 18 years of age.
  • Two consecutive i STAT potassium values, measured 60 (+/- 15) minutes apart, both >/= 5.1 mmol/L and measured within 1 day before the first dose of ZS on Acute Phase Study Day 1.
  • Ability to have repeated blood draws or effective venous catheterization.
  • Women of must be using 2 forms of medically acceptable (at least 1 barrier method) and have a negative pregnancy test at Acute Phase Study Day 1. Women who are surgically sterile or those who are for at least 2 years are not considered to be of childbearing potential.
  • Controlled diabetic subjects.

Exclusion criteria

Exclusion Criteria:

  • Pseudohyperkalemia signs and symptoms, such as hemolyzed blood specimen due to excessive fist clenching to make veins prominent, difficult or traumatic venipuncture, or history of severe leukocytosis or thrombocytosis.
  • Subjects treated with lactulose, rifaximin, or other non-absorbed antibiotics for hyperammonemia within 7 days prior to first dose of ZS on Acute Phase Study Day 1.
  • Subjects treated with sodium polystyrene sulfonate (SPS; eg, Kayexalate®) or calcium polystyrene sulfonate (eg, Resonium®) within 3 days prior to first dose of ZS on Acute Phase Study Day 1.
  • Subjects with a of less than 12 months.
  • Subjects who are severely physically or mentally incapacitated and who, in the opinion of investigator, are unable to perform the subjects' tasks associated with the protocol.
  • Women who are pregnant, lactating, or planning to become pregnant.
  • Subjects with diabetic ketoacidosis.
  • Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.
  • Known or previous anaphylaxis to ZS or to components thereof.
  • Treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry.
  • Subjects with cardiac arrhythmias that require immediate treatment.
  • Subjects on dialysis.
  • Subjects randomized into the previous ZS-002, ZS-003, ZS-004, or ZS-004E studies.
  • Documented \<15 mL/min within 90 days prior to study entry.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
751 participants (actual)

Study arms

  • Experimental
    Sodium Zirconium Cyclosilicate

    Drug: Sodium Zirconium Cyclosilicate

Interventions

  • Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.

    Also known as: ZS

06

What researchers measure

Primary outcomes

  1. Percent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute Phase

    Percentage of subjects with S-K values between 3.5 and 5.0 mmol/L, inclusive at the end of the Acute Phase - ITT Population

    Time frame: 72 Hours

  2. Percentage of Participants With Mean S-K Values ≤ 5.1 mmol/L During Extended Dosing Phase Days 85 to 365

    Percentage of subjects with mean S-K values ≤ 5.1 mmol/L during Extended Dosing Phase - ITT Population

    Time frame: Study Days 85 to 365

Secondary outcomes

  1. Proportion of Subjects With Mean S-K Between 3.5 and 5.5 mmol/L, Inclusive Months 3 to 12

    Proportion of Subjects with mean S-K between 3.5 and 5.5 mmol/L during Extended Dosing Phase - ITT Population

    Time frame: Study Days 85 to 365

  2. Mean S-K Levels Months 3 to 12, Months 6 to 9, and Months 9 to 12.

    Mean S-K levels months 3 to 12(EP Days 85, 113, 141, 176, 211, 239, 267, 295, 330, 365 and EOS),months 6 to 9, and months 9 to 12.

    Time frame: Study days 85 to 365

07

Results

Posted Jun 27, 2018

Participant flow

Participants took part in the study at 56 sites in the Unites States, Australia, South Africa, Germany, the United Kingdom and the Netherlands from 23 June 2014 to 04 November 2016

Acute Phase: ZS 10 g TID
Participant flow — Acute Phase: ZS 10 g TID
MilestoneSubject Disposition
Started751
Completed746
Not completed5
Withdrew: Participant's compliance1
Withdrew: Hypo- or hyperkalemia1
Withdrew: Protocol violation1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject1
Extended Dosing Phase: ZS
Participant flow — Extended Dosing Phase: ZS
MilestoneSubject Disposition
Started746
Completed466
Not completed280
Withdrew: Adverse event51
Withdrew: Expected progression of ckd40
Withdrew: Hypokalemia9
Withdrew: Sponsor's decision5
Withdrew: Met ecg withdrawal criteria7
Withdrew: Withdrawal by subject81
Withdrew: Physician decision8
Withdrew: Lost to follow-up31
Withdrew: Protocol violation2
Withdrew: Death8
Withdrew: Subject compliance17
Withdrew: Hyperkalemia5
Withdrew: Various reasons16

Outcome measures

SecondaryProportion of Subjects With Mean S-K Between 3.5 and 5.5 mmol/L, Inclusive Months 3 to 12

Proportion of Subjects with mean S-K between 3.5 and 5.5 mmol/L during Extended Dosing Phase - ITT Population

Time frame:
Study Days 85 to 365
Reported as:
Number · Proportion of participants
Proportion of Subjects With Mean S-K Between 3.5 and 5.5 mmol/L, Inclusive Months 3 to 12
Proportion of participantsProportion
Proportion of Subjects With Mean S-K Between 3.5 and 5.5 mmol/L, Inclusive Months 3 to 120.985 (0.972 to 0.993)
SecondaryMean S-K Levels Months 3 to 12, Months 6 to 9, and Months 9 to 12.

Mean S-K levels months 3 to 12(EP Days 85, 113, 141, 176, 211, 239, 267, 295, 330, 365 and EOS),months 6 to 9, and months 9 to 12.

Time frame:
Study days 85 to 365
Reported as:
Mean · mmol/L
Mean S-K Levels Months 3 to 12, Months 6 to 9, and Months 9 to 12.
mmol/LMean S-K Levels Months 3 to 12,6 to 9, and 9 to 12
Acute Phase Baseline5.59 ± 0.425
Extended Dosing Days 85 to 365/End of Study4.66 ± 0.379
Extended Dosing Days 211 to 2674.68 ± 0.404
Extended Dosing Days 295 to 3654.62 ± 0.401
PrimaryPercent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute Phase

Percentage of subjects with S-K values between 3.5 and 5.0 mmol/L, inclusive at the end of the Acute Phase - ITT Population

Time frame:
72 Hours
Reported as:
Number · Percentage of participants
Percent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute Phase
Percentage of participantsPercentage
Percent of Participants With Restoration of Normal Serum Potassium (S-K) Values (3.5 to 5.0 mmol/L, Inclusive) at the End of the Acute Phase77.9 (74.8 to 80.9)
PrimaryPercentage of Participants With Mean S-K Values ≤ 5.1 mmol/L During Extended Dosing Phase Days 85 to 365

Percentage of subjects with mean S-K values ≤ 5.1 mmol/L during Extended Dosing Phase - ITT Population

Time frame:
Study Days 85 to 365
Reported as:
Number · Percentage of participants
Percentage of Participants With Mean S-K Values ≤ 5.1 mmol/L During Extended Dosing Phase Days 85 to 365
Percentage of participantsPercentage
Percentage of Participants With Mean S-K Values ≤ 5.1 mmol/L During Extended Dosing Phase Days 85 to 36588.4 (85.7 to 90.8)

Adverse events

Collected over One year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acute Phase: ZS0/751 (0%)1/751 (0.1%)11/751 (1.5%)
Extended Dosing Phase: ZS8/746 (1.1%)161/746 (21.6%)386/746 (51.7%)
Most frequent serious events
Showing 10 of 136
Most frequent serious events
EventAcute Phase: ZSExtended Dosing Phase: ZS
PneumoniaInfections and infestations0/75114/746
Cardiac failure congestiveCardiac disorders0/75111/746
Chest painGeneral disorders0/75111/746
OsteomyelitisInfections and infestations0/7518/746
Renal failure acuteRenal and urinary disorders0/7518/746
CellulitisInfections and infestations0/7517/746
Acute myocardial infarctionCardiac disorders0/7516/746
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/7515/746
DyspnoeaRespiratory, thoracic and mediastinal disorders0/7515/746
HypertensionVascular disorders0/7514/746
Most frequent other events
Most frequent other events
EventAcute Phase: ZSExtended Dosing Phase: ZS
HypertensionVascular disorders1/75178/746
Oedema peripheralGeneral disorders1/75172/746
NauseaGastrointestinal disorders4/75156/746
Urinary tract infectionInfections and infestations3/75155/746
ConstipationGastrointestinal disorders2/75146/746
AnaemiaBlood and lymphatic system disorders0/75142/746
Upper respiratory infectionInfections and infestations0/75137/746

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Acute Phase: ZS
Mean63.6 ± 13.03
Sex: Female, Male
Sex: Female, Male(Participants)Acute Phase: ZS
Female303
Male448
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Acute Phase: ZS
Asian25
Native Hawaiian or Other Pacific Islander3
Black or African American89
White624
Other10
Use of RAAS inhibitor medication
Use of RAAS inhibitor medication(Participants)Acute Phase: ZS
Count of participants527
Co-morbidities at baseline
Co-morbidities at baseline(Participants)Acute Phase: ZS
Diabetes mellitus471
Chronic kidney disease513
Heart Failure285
Baseline eGFR
Baseline eGFR(Participants)Acute Phase: ZS
<1546
15-<30243
30-<60263
≥60190
Missing9
Acute Phase baseline Serum Potassium
Acute Phase baseline Serum Potassium(Participants)Acute Phase: ZS
<5.5 mmol/L287
5.5<6.0 mmol/L338
≥6.0 mmol/L126
08

Study locations

51 sites
  • Scottsboro, Alabama 35768, United States
  • Tempe, Arizona 85284, United States
  • Tucson, Arizona 85724, United States
  • Chula Vista, California 90717, United States
  • Los Angeles, California 90022, United States
  • Paramount, California 90723, United States
  • Riverside, California 92505, United States
  • Sacramento, California 95825, United States
  • Whittier, California 90603, United States
  • Denver, Colorado 80230, United States
  • Brandon, Florida 33511, United States
  • DeLand, Florida 32720, United States
  • Hudson, Florida 34667, United States
  • Lauderdale Lakes, Florida 33313, United States
  • Miami Lakes, Florida 33018, United States
  • Miami, Florida 33015, United States
  • Miami, Florida 33125, United States
  • New Smyrna Beach, Florida 32168, United States
  • New Smyrna, Florida 32168, United States
  • Tampa, Florida 33614, United States
  • Winter Park, Florida 32789, United States
  • Columbus, Georgia 31901, United States
  • Evergreen Park, Illinois 60805, United States
  • Joliet, Illinois 60435, United States
  • Paducah, Kentucky 42003, United States
  • Shreveport, Louisiana 71101, United States
  • Chesterfield, Michigan 48047, United States
  • Kansas City, Missouri 64411, United States
  • Saint Louis, Missouri 63110, United States
  • Great Neck, New York 11021, United States
  • Providence, Rhode Island 02903, United States
  • Orangeburg, South Carolina 29118, United States
  • Sumter, South Carolina 29150, United States
  • Chattanooga, Tennessee 37408, United States
  • San Antonio, Texas 78215, United States
  • San Antonio, Texas 78229, United States
  • Saint George, Utah 84770, United States
  • Gosford, New South Wales 2250, Australia
  • Woolloongabba, Queensland 4102, Australia
  • Heidelberg, Victoria 3084, Australia
  • Melbourne, Victoria 3073, Australia
  • Parkville, Victoria 3050, Australia
  • Berlin, 13353, Germany
  • Stuttgart, 70376, Germany
  • Amsterdam, 1105 AZ, Netherlands
  • Lasi, 700503, Romania
  • Cape Town, 7925, South Africa
  • Meyerspark, South Africa
  • Port Elizabeth, 6001, South Africa
  • Somerset West, 7130, South Africa
  • Leicester, LE1 9HN, United Kingdom
09

References and documents

Publications

  • Roger SD, Lavin PT, Lerma EV, McCullough PA, Butler J, Spinowitz BS, von Haehling S, Kosiborod M, Zhao J, Fishbane S, Packham DK. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study. Nephrol Dial Transplant. 2021 Jan 1;36(1):137-150. doi: 10.1093/ndt/gfz285. PubMed 32030422 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Nov 2016, 29 months.

Results were first posted in Jun 2018, 1 year 6 months after primary completion.

Of 18 phase 3 interventional studies under Hyperkalemia, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2014
First posted
Jun 13, 2014
StartActual
Jun 30, 2014
Primary completionActual
Nov 30, 2016
CompletionActual
Nov 30, 2016
Results first posted
Jun 27, 2018
Last update
Jun 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02163499
Lead sponsor
ZS Pharma, Inc.
Responsible party
Sponsor
First posted
Jun 13, 2014
Start date
Jun 30, 2014
Primary completion
Nov 30, 2016
Completion
Nov 30, 2016
Results posted
Jun 27, 2018
Last update
Jun 27, 2018

Study contacts

Henrik Rasmussen, MD, PhD
study chair · ZS Pharma, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium zirconium cyclosilicate

Start the discussion